Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinengotinib in FGFR2-altered advanced intrahepatic cholangiocarcinoma
NCT07328919Phase 3Not yet recruiting
- Sponsor
- TransThera Biosciences
- Start
- Jan 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tinengotinib in intrahepatic cholangiocarcinoma (ICC), sponsored by TransThera Biosciences. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
tinengotinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT07328919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07328919.